Aurobindo gets USFDA nod for anticoagulant

Aurobindo Pharma said it had received final nod from the U.S. Food and Drug Administration (USFDA) to manufacture and market Bivalirudin injection, 250 mg/vial. The product, indicated for use as an anticoagulant in patients with certain conditions, is proposed to be rolled out in September. The approved ANDA is a generic equivalent to the reference listed drug product Angiomax injection of The Medicines Company.

Source: Read Full Article